• 제목/요약/키워드: Cancer biomarker

검색결과 441건 처리시간 0.038초

MicroRNA-31 과발현을 이용한 대장암의 예후예측 및 전이예측 바이오마커 발굴 (Overexpression of MicroRNA-31 as a Promising Biomarker for Prognosis and Metastasis in Human Colorectal Cancer)

  • 허근
    • 생명과학회지
    • /
    • 제26권6호
    • /
    • pp.705-710
    • /
    • 2016
  • 대장암은 세계적으로 3번째로 흔한 암종이며, 암으로 인한 사망의 주요 원인이 되고 있다. 비록 다양한 진단방법이나 치료 방법이 이용되고는 있으나 병의 진행에 관여하는 분자메커니즘 이해의 부족 때문에 여전히 완전한 치료는 어려운 실정이다. 마이크로알엔에이는 단백질 정보를 코딩하고 있지 않은 작은 알엔에이 단편이다. 이러한 마이크로알엔에이는 특정 유전자의 전사과정 또는 번역과정을 조절하는 강력한 유전자 조절자로서의 기능을 가진다. 암의 발생과정에서 중요한 세포신호 전달 과정의 손상이 빈번하게 발생 하는데, 다양한 마이크로알엔에이의 이상발현이 그 원인이 되고 있다. 마이크로알엔에이-31은 암유전자의 역할을 하며 발암과정에 관여하는 다양한 유전자를 조절한다고 알려져 있다. 따라서, 본 연구에서는 대장암에서 마이크로알엔에이-31 발현의 임상적의의를 규명하고자 하였다. 175례의 대장암 조직과 16례의 정상 대장조직에서 실시간 유전자 증폭장치를 이용하여 마이크로알엔에이-31의 발현을 분석하고, 임상병리적 요인들과의 상관관계를 분석하고 임상적 유용성을 연구해 보았다. 마이크로알엔에이-31은 정상조직에 비해 대장암 조직에서 과발현이 되어 있었다. 175례 대장암 조직을 이용한 분석에서 마이크로알엔에이-31의 발현은 병기의 진행 정도에 따라 발현이 증가 되고 있었으며, 실제 마이크로알엔에이-31의 발현이 높은 대장암 환자군의 생존률이 그렇지 않은 환자군에 비해 통계적으로 유의하게 나쁜 것으로 확인 되었다. Cox 비례위험 모형과 로지스틱 회귀 모형을 이용한 분석에서 마이크로알엔에이-31의 과발현이 직접적으로 대장암 환자의 예후 및 원발전이와 연관성이 있는 것이 확인 되었다. 따라서, 이상의 연구결과를 종합해볼 때 대장암에서 과발현 된 마이크로알엔에이-31은 대장암 환자의 예후예측 및 전이예측 바이오마커로서의 활용 가능성이 높다고 볼 수 있다.

NEW TNF-$\alpha$ RELEASING INHIBITORS AS CANCER PREVENTIVE AGENTS FROM TRADITIONAL HERBAL MEDICINE, AND HNRNP B1, A NEW EFFECTIVE BIOMARKER FOR CHEMOPREVENTION OF HUMAN LUNG CANCER

  • Fujiki, Hirota;Suganuma, Masami;Okabe, Sachiko;Fujimoto, Nobukazu;Yoshida, Takashi;Sueoka, Naoko;Sueoka, Eisaburo
    • 한국독성학회:학술대회논문집
    • /
    • 한국독성학회 2001년도 International Symposium on Dietary and Medicinal Antimutgens and Anticarcinogens
    • /
    • pp.22-23
    • /
    • 2001
  • Based on the success of green tea as a cancer preventive, herbal medicines are now also attracting attention as potential sources of cancer preventive agents. Using inhibition of TNF-$\alpha$ release assay, we studied Acer nikoense (Megusurino-ki in Japanese): Inhibitory potential was found in the leaf extract, and the main active constituents were identified as geraniin and corilagin. The $IC_{50}$/ values for TNF-$\alpha$ release inhibition were 43 $\mu$M for geraniin and 76 $\mu$M for corilagin, whereas that for (-)-epigallocatechin gallate (EGCG)was 26 $\mu$M.(omitted)

  • PDF

Ranking Candidate Genes for the Biomarker Development in a Cancer Diagnostics

  • Kim, In-Young;Lee, Sun-Ho;Rha, Sun-Young;Kim, Byung-Soo
    • 한국생물정보학회:학술대회논문집
    • /
    • 한국생물정보시스템생물학회 2004년도 The 3rd Annual Conference for The Korean Society for Bioinformatics Association of Asian Societies for Bioinformatics 2004 Symposium
    • /
    • pp.272-278
    • /
    • 2004
  • Recently, Pepe et al. (2003) employed the receiver operating characteristic (ROC) approach to rank candidate genes from a microarray experiment that can be used for the biomarker development with the ultimate purpose of the population screening of a cancer, In the cancer microarray experiment based on n patients the researcher often wants to compare the tumor tissue with the normal tissue within the same individual using a common reference RNA. This design is referred to as a reference design or an indirect design. Ideally, this experiment produces n pairs of microarray data, where each pair consists of two sets of microarray data resulting from reference versus normal tissue and reference versus tumor tissue hybridizations. However, for certain individuals either normal tissue or tumor tissue is not large enough for the experimenter to extract enough RNA for conducting the microarray experiment, hence there are missing values either in the normal or tumor tissue data. Practically, we have $n_1$ pairs of complete observations, $n_2$ 'normal only' and $n_3$ 'tumor only' data for the microarray experiment with n patients, where n=$n_1$+$n_2$+$n_3$. We refer to this data set as a mixed data set, as it contains a mix of fully observed and partially observed pair data. This mixed data set was actually observed in the microarray experiment based on human tissues, where human tissues were obtained during the surgical operations of cancer patients. Pepe et al. (2003) provide the rationale of using ROC approach based on two independent samples for ranking candidate gene instead of using t or Mann -Whitney statistics. We first modify ROC approach of ranking genes to a paired data set and further extend it to a mixed data set by taking a weighted average of two ROC values obtained by the paired data set and two independent data sets.

  • PDF

Clinical Significance and Prognostic Value of Pentraxin-3 as Serologic Biomarker for Lung Cancer

  • Zhang, Dai;Ren, Wei-Hong;Gao, Yun;Wang, Nian-Yue;Wu, Wen-Jun
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권7호
    • /
    • pp.4215-4221
    • /
    • 2013
  • Purposes: Lung cancer is prevalent worldwide and improvements in timely and effective diagnosis are need. Pentraxin-3 as a novel serum marker for lung cancer (LC) has not been validated in large cohort studies. The aim of the study was to assess its clinical value in diagnosis and prognosis. Methods: We analyzed serum PTX-3 levels in a total of 1,605 patients with LC, benign lung diseases and healthy controls, as well as 493 non-lung cancer patients including 12 different types of cancers. Preoperative and postoperative data were further assessed in patients undergoing LC resection. The diagnostic performance of PTX-3 for LC and early-stage LC was assessed using receiver operating characteristics (ROC) by comparing with serum carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA 21-1). Results: Levels of PTX-3 in serum were significantly higher in patients with LC than all controls. ROC curves showed the optimum diagnostic cutoff was 8.03ng/mL (AUC 0.823, [95%CI 0.789-0.856], sensitivity 72.8%, and specificity 77.3% in the test cohort; 0.802, [95%CI 0.762-0.843], sensitivity 69.7%, and specificity 76.4% in the validate cohort). Similar diagnostic performance of PTX-3 was observed for early-stage LC. PTX-3 decreased following surgical resection of LC and increased with tumor recurrence. Significantly elevated PTX-3 levels were also seen in patients with non-lung cancers. Conclusions: The present data revealed that PTX-3 was significantly increased in both tissue and serum samples in LC patients. PTX-3 is a valuable biomarker for LC and improved identification of patients with LC and early-stage LC from those with non-malignant lung diseases.

Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases

  • Laohaviroj, Marut;Chamgramol, Yaovalux;Pairojkul, Chawalit;Mulvenna, Jason;Sripa, Banchob
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권1호
    • /
    • pp.201-205
    • /
    • 2016
  • Cholangiocarcinoma (CCA) is generally a rare primary liver tumor of the bile duct with extremely poor clinical outcomes due to late diagnosis. Osteopontin (OPN) is the most abundant expressed gene in intrahepatic CCA and its involvement in tumor aggressiveness suggests it could be a useful prognostic biomarker. However, the prognostic significance of OPN expression in CCA is still controversial. We therefore immunohistochemically studied OPN expression in 354 resected CCAs and correlated the results with patient clinicopathological parameters. OPN expression was separately scored according to the percentage of cancer cells or degree of stromal tissue staining and classified as low (score 0-1) and high (score 2-3). OPN expression in CCA cells was found in 177 out of 354 patients (56.5%), whereas stroma was positive in 185 out of 354 patients (52.3%). Univariate analysis with several of the aforementioned parameters revealed that stromal but not cancer cell OPN expression was significantly associated with tumor size, tumor direct invasion into normal liver parenchyma, regional lymph node metastasis and higher staging. The combination of cancer cell and stromal OPN expression demonstrated a positive trend for linkage with lymph node metastasis. Multivariate analysis identified gender, the presence of lymphatic permeation and lymph node metastasis, but not OPN expression, as independent prognostic factors. This study confirms the presence of stromal OPN expression in tumor aggressiveness but not survival in CCA patients.

G1/S-specific Cyclin-D1 Might be a Prognostic Biomarker for Patients with Laryngeal Squamous Cell Carcinoma

  • Zhang, Ying-Yao;Xu, Zhi-Na;Wang, Jun-Xi;Wei, Dong-Min;Pan, Xin-Liang
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제13권5호
    • /
    • pp.2133-2137
    • /
    • 2012
  • Objective: To investigate the prognostic role of antigen KI-67 (Ki-67) and G1/S-specific cyclin-D1 (cyclin-D1) in patients with laryngeal squamous cell carcinoma (LSCC). Methods: Immunohistochemical staining (IHS) was used to determine the protein expression of Ki-67 and cyclin-D1 in LSCC tissues. Kaplan-Meier survival curves was calculated with reference to Ki-67 and cyclin-D1 levels. Results: Cyclin-D1 and Ki67 were expressed in the nuclei of cancer cells. Among the total of 92 cancer tissues examined by immunohistochemistry, 60 (65.22%) had cyclin-D1 overexpression and 56 (60.87%) had Ki67 overexpression. Cyclin-D1 overexpression is associated with the advanced stage of the cancer (P=0.029), but not with gender, age, stage of cancer, histological differentiation, anatomical site, smoking history and alcohol consumption history. Ki67 overexpression is not associated with the advanced stage, gender, age, histological differentiation, anatomical site, smoking history and alcohol consumption history. A statistically significant correlation was found between lymph node status and the expression of Ki67 (p = 0.025). Overexpression of cyclin-D1 was correlated to shorter relapse-free survival period (P<0.001). Conclusions: Overexpression of cyclin-D1 can be used as a marker to predict relapse in patients with LSCC after primary curative resection.

Problems in the Pathologic Diagnosis of Suspected Lung Cancer

  • Soo Han Kim;Mi-Hyun Kim;Min Ki Lee;Jung Seop Eom
    • Tuberculosis and Respiratory Diseases
    • /
    • 제86권3호
    • /
    • pp.176-182
    • /
    • 2023
  • Since the introduction of low-dose computed tomography (CT) screening for patients at high risk of lung cancer, the detection rate of suspicious lung cancer has increased. In addition, there have been many advances in therapeutics targeting oncogenic drivers in non-small cell lung cancer. Therefore, accurate pathological diagnosis of lung cancer, including molecular diagnosis, is increasingly important. This review examines the problems in the pathological diagnosis of suspected lung cancer. For successful pathological diagnosis of lung cancer, clinicians should determine the appropriate modality of the diagnostic procedure, considering individual patient characteristics, CT findings, and the possibility of complications. Furthermore, clinicians should make efforts to obtain a sufficient amount of tissue sample using non- or less-invasive procedures for pathological diagnosis and biomarker analysis.

Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma

  • Ni, Xiao-Chun;Yi, Yong;Fu, Yi-Peng;He, Hong-Wei;Cai, Xiao-Yan;Wang, Jia-Xing;Zhou, Jian;Fan, Jia;Qiu, Shuang-Jian
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권24호
    • /
    • pp.10713-10718
    • /
    • 2015
  • Purpose: To investigate the prognostic value of serum amyloid A (SAA) in patients with hepatocellular carcinoma (HCC) undergoing surgery. Materials and Methods: Preoperative serum samples of 328 patients with HCC who underwent curative resection and of 47 patients with benign liver lesion were assayed. Serum levels of SAA were measured by enzyme-linked immunosorbent assay and its correlations with clinicopathological characteristics and survival were explored. Results: Levels of SAA were significantly higher in patients with HCC than those with benign liver lesion. There were strong correlations between preoperative serum SAA level and tumor size and more advanced BCLC stage. On univariate analysis, elevated SAA was associated with reduced disease-free survival and overall survival (p=0.001 and 0.03, respectively). Multivariate analyses showed that serum SAA level was an independent prognostic factor for overall survival (hazard ratio 2.80, p=0.01). Conclusions: High SAA serum level is a novel biomarker for the prognosis of HCC patients.

MicroRNAs: promising biomarkers for diagnosis and therapeutic targets in human colorectal cancer metastasis

  • Hur, Keun
    • BMB Reports
    • /
    • 제48권4호
    • /
    • pp.217-222
    • /
    • 2015
  • Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death worldwide. Distant metastasis is a major cause of mortality in CRC. MicroRNAs (miRNAs) are small non-coding RNA molecules involved in the post-transcriptional and translational regulation of gene expression. Many miRNAs are aberrantly expressed in cancer and influence tumor progression. Accumulating studies suggest that multiple miRNAs are actively involved in the CRC metastasis process. Thus, we aim to introduce the role of miRNAs in multi-steps of CRC metastasis, including cancer cell invasion, intravasation, circulation, extravasation, colonization, angiogenesis, and epithelial-mesenchymal transition (EMT). Moreover, we suggest the potential application of miRNAs as biomarkers for CRC patients with metastasis. [BMB Reports 2015; 48(4): 217-222]

의사결정트리 프로그램 개발 및 갑상선유두암에서 질량분석법을 이용한 단백질 패턴 분석 (Development of Decision Tree Software and Protein Profiling using Surface Enhanced laser Desorption/lonization - Time of Flight - Mass Spectrometry (SELDI-TOF-MS) in Papillary Thyroid Cancer)

  • 윤준기;이준;안영실;박복남;윤석남
    • Nuclear Medicine and Molecular Imaging
    • /
    • 제41권4호
    • /
    • pp.299-308
    • /
    • 2007
  • 본 연구의 목적은 의사결정트리를 생성하는 생물정보학 프로그램을 개발하고, 이를 갑상선유두암 혈청의 질량분석자료로 시험해 보는 것이다. 대상 및 방법: C4.5를 커스터마이징하여 의사결정트리 분석을 수행할 수 있는 'Protein analysis'라는 프로그램을 개발하였다 61개의 혈청시료(갑상선유두암 27, 자가면역성 갑상선염 17, 대조군 17)를 일정 기간 동안 순차적으로 냉동한 후 실온에서 일시에 해동하여 분석에 사용하였다. 모든 시료는 탈지질화 과정을 거쳐 준비한 후, 2종류의 단백질칩(CM10, IMAC3)에 각각 60개, 50개 시료를 적용하였다. 갑상선유두암의 특징적인 단백질 패턴을 찾기 위해 질량분석기를 이용하여 단백질칩을 분석했다. 'Protein analysis' 프로그램을 이용하여 단백질분포 자료로부터 의사결정트리를 작성하고, 생체표지자 후보물질을 검출하였다. CM10칩에서 발견된 생체표지자 후보물질을 무작위 표본추출 방법을 이용하여 검증하였다. 결과: 단백질분포 자료의 훈련과 검증이 가능한 의사결정트리 프로그램이 개발되었으며, 이 프로그램은 트리 구조와 노드 정보, 트리 구성 과정을 표시하는 3개의 창으로 구성되었다. CM10칩을 이용한 분석에서 총 113개의 단백질 피크 중 23개가 3그룹 간에 유의한 차이가 있었으며, IMAC3는 41개의 단백질 피크 중 8개가 3그룹 간에 유의한 차이가 있었다. 3그룹 분석에서 의사결정트리는 CM10칩과 IMAE3의 단백질분포 자료로부터 각각 60개와 50개의 시료를 높은 정확도로 분류하였으며(오차율 = 각각 3.3%, 2.0%), 각각 4개와 7개의 생체표지자 후보물질을 검출하였다. 암시료와 비암시료를 구분하는 2그룹 분석 에서, 의사결정트리는 모든 암시료를 정확히 구분하였으며(모두 오차율 = 0%), CM10칩을 이용한 분석에서는 단일 노드를 사용하고, IMAC3칩을 이용한 분석에서는 여러 개의 노드를 사용하였다. CM10칩의 단백질 분포자료를 5번의 무작위 추출에 의해 시행한 검증에서 암시료와 비암시료를 구분하는데 높은 정확도를 보였으나(정확도 = 98%, 54/55), 3그룹을 구분할 때는 중등도의 정확도를 보였다(정확도 = 65%, 36/55). 결론: 우리가 개발한 프로그램은 질량분석 자료로부터 성공적으로 의사결정트리를 생성하고, 생체표지자 후보물질을 검출할 수 있었다. 따라서 이 프로그램은 혈청 시료를 이용한 생체표지자 발굴 및 갑상선유두암의 추적관찰에 유용하게 사용될 수 있을 것이다.